» Articles » PMID: 31205821

Integrative Analysis of Common Genes and Driver Mutations Implicated in Hormone Stimulation for Four Cancers in Women

Overview
Journal PeerJ
Date 2019 Jun 18
PMID 31205821
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the leading cause of death of women worldwide, and breast, ovarian, endometrial and cervical cancers contribute significantly to this every year. Developing early genetic-based diagnostic tools may be an effective approach to increase the chances of survival and provide more treatment opportunities. However, the current cancer genetic studies are mainly conducted independently and, hence lack of common driver genes involved in cancers in women. To explore the potential common molecular mechanism, we integrated four comprehensive literature-based databases to explore the shared implicated genetic effects. Using a total of 460 endometrial, 2,068 ovarian, 2,308 breast and 537 cervical cancer-implicated genes, we identified 52 genes which are common in all four types of cancers in women. Furthermore, we defined their potential functional role in endogenous hormonal regulation pathways within the context of four cancers in women. For example, these genes are strongly associated with hormonal stimulation, which may facilitate rapid diagnosis and treatment management decision making. Additional mutational analyses on combined the cancer genome atlas datasets consisting of 5,919 gynaecological and breast tumor samples were conducted to identify the frequently mutated genes across cancer types. For those common implicated genes for hormonal stimulants, we found that three quarter of 5,919 samples had genomic alteration with the highest frequency in (22%), followed by (19%), (14%), (13%), (13%) and (11%). We also identified 38 hormone related genes, eight of which are associated with the ovulation cycle. Further systems biology approach of the shared genes identified 20 novel genes, of which 12 were involved in the hormone regulation in these four cancers in women. Identification of common driver genes for hormone stimulation provided an unique angle of involving the potential of the hormone stimulants-related genes for cancer diagnosis and prognosis.

Citing Articles

Comprehensive analysis of hub genes associated with cisplatin-resistance in ovarian cancer and screening of therapeutic drugs through bioinformatics and experimental validation.

Zhu Y, Chen X, Tang R, Li G, Yang J, Hong S J Ovarian Res. 2024; 17(1):142.

PMID: 38987777 PMC: 11234624. DOI: 10.1186/s13048-024-01461-w.


A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical Cancer.

Eksteen C, Riedemann J, Rass A, Plessis M, Botha M, van der Merwe F Cancer Control. 2024; 31:10732748241261539.

PMID: 38881031 PMC: 11181891. DOI: 10.1177/10732748241261539.


The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies.

Czegle I, Huang C, Soria P, Purkiss D, Shields A, Wappler-Guzzetta E Life (Basel). 2023; 13(4).

PMID: 37109525 PMC: 10145875. DOI: 10.3390/life13040996.


Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists.

Morshed A, Azad S, Mia M, Uddin M, Ema T, Yeasin R Mol Divers. 2022; 27(6):2651-2672.

PMID: 36445532 DOI: 10.1007/s11030-022-10573-8.


Metalloproteases in gonad formation and ovulation.

Zhu Y Gen Comp Endocrinol. 2021; 314:113924.

PMID: 34606745 PMC: 8576836. DOI: 10.1016/j.ygcen.2021.113924.


References
1.
. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

2.
Hartwell L, Hopfield J, Leibler S, Murray A . From molecular to modular cell biology. Nature. 1999; 402(6761 Suppl):C47-52. DOI: 10.1038/35011540. View

3.
Henderson B, Feigelson H . Hormonal carcinogenesis. Carcinogenesis. 2000; 21(3):427-33. DOI: 10.1093/carcin/21.3.427. View

4.
Zhang , Wang H . MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des. 2000; 6(4):393-416. DOI: 10.2174/1381612003400911. View

5.
Liao D, Dickson R . c-Myc in breast cancer. Endocr Relat Cancer. 2000; 7(3):143-64. DOI: 10.1677/erc.0.0070143. View